This article is more than 5 years old. Information may no longer be current.
DermTech enters into preferred provider agreements
Click Here to Manage Email Alerts
DermTech announced in a press release that it has completed contracts for payments with two third-party payor networks, MultiPlan and FedMed.
The La Jolla, California-based commercial stage molecular dermatology company develops noninvasive gene expression tests to assist in the clinical diagnosis of skin cancer and other conditions, according to the release. MultiPlan and FedMed have more than 100 million members, with nearly 1.5 million providers participating in them.
DermTech technology uses an adhesive patch to allow for analysis of skin biopsy samples collected noninvasively, the release reported.
“We are very pleased to become a participating member with these large payor networks making our Pigmented Lesion Assay significantly more accessible and affordable to many patients with skin cancer concerns,” Steve Kemper, MBA, DermTech CFO, stated in the release. “Our ability to gain agreements with companies such as FedMed and MultiPlan serves as growing evidence that the health care community is recognizing the important role of molecular pathology in the detection of skin cancer.”
Reference: www.dermtech.com